1. Alter, C.A., W.C. Boyar, A. Wasley, S.C. Gerhardt, J.M. Liebman and P.L. Wood, 1988, Dopamine neurochemical profile of atypical antipsychotics resembles that of D-1 antagonists, Naunyn-Schmiedeberg's Arch. Pharmacol. 338, 162.
2. Angst, J., D. Bente, P. Berner, H. Heimann, H. Helmchen and H. Hippius, 1971, Das klinische Wirkungsbild von Clozapin (Untersuchung mit dem AMP-system), Pharmakopsychiatrie 4, 201.
3. Bersani, G., A. Grispini, S. Marini, A. Pasini, M. Valducci and N. Ciani, 1986, Neuroleptic-induced extrapyramidal side effects: clinical perspectives with ritanserin (R 55667), a new selective 5-HT2 receptor blocking agent, Curr. Ther. Res. 40, 492.
4. Boyson, S.J., P. McGonigle, G.R. Luthin, B.B. Wolfe and P.B. Molinoff, 1988, Effects of chronic administration of neuroleptic and anticholinergic agents on densities of D2 dopamine and muscarinic cholinergic receptors in rat striatum, J. Pharmacol. Exp. Ther., 244, 987.
5. Carter, C.J. and C.J. Pycock, 1977, Possible importance of 5-hydroxytryptamine in neuroleptic-induced catalepsy in rats, Br. J. Pharmacol. 60, 267.